1800 244 735

Helpline (02) 9874 9777

Could HD be caused by amino acid deficiency?

All the proteins in our body are made of tiny chemical building blocks, called amino acids. The internet was recently buzzing about a newly discovered link between one of these amino acids, cysteine, and Huntington’s Disease. Is it true, as some headlines suggested, that “Brain Degeneration In Huntington’s Disease Caused By Amino Acid Deficiency”?

Amino acids and proteins

Most of the work in our cells is carried out by tiny machines called proteins. Proteins are created by cells using instructions found in genes, encoded in our DNA.

Proteins are assembled in the cell by the sequential addition of tiny chemicals to a growing chain, sort of like beads on a string. The tiny chemicals that make up proteins are called amino acids, thanks to their chemical structure.

In cells from mammals, such as humans, there is a library of about 21 amino acids that are used to make proteins. From the simple sequences of amino acids are built all the complex machines our cells need to work.

Each of the 20 or so amino acids needed by our bodies must be present in sufficient amounts, or else our cells have a hard time making the proteins they need. Some amino acids are easy for our body to synthesize – these are “non-essential” amino acids. Others are more tricky to make, so we need a source of them in our diet, making them “essential amino acids”.

The HD connection

A group of scientists at Johns Hopkins University, led by Solomon Snyder, is interested in how the body makes and degrades one of these amino acids, called cysteine. In fact, Snyder’s group has a long-standing interest in a by-product of cysteine metabolism, a rotten-egg-smelling gas, called hydrogen sulfide.

One of the ways the body makes cysteine and hydrogen sulfide is through the activity of a protein called cystathionine gamma-lyase (CSE). To study the role of hydrogen sulfide in the body, Snyder’s team made a mouse that lacked the gene that tells cells how to make the CSE protein. This so-called knockout mouse approach is a common way to study the function of genes in the lab – just get rid of them and then see what happens to the resulting animals.

When suspended by their tails, mice that lacked the CSE gene made a very funny clasping motion – bringing all four of their limbs in towards their body. A number of mice with brain problems, including some HD mice, make this same strange clasping motion. It reminded Snyder’s group so much of HD mice that they decided to see if there was any connection between the activity of CSE and HD.

Cell findings

First, Snyder’s group looked at brains donated by people affected by HD. They found that the levels of CSE were decreased in the brains of HD patients, which might suggest that they have less CSE activity. This is an interesting hint that something might be happening, but so many things change in the brains of HD patients by the time they die that we have to be careful interpreting this kind of information.

Human samples are also hard to work with, so Snyder’s group turned to cells from HD mice. Again, in this cleaner system they saw reduced CSE levels. When they looked at how fast these cells made cysteine, the amino acid made by CSE, that rate was lower as well, agreeing with their idea that lower activity of CSE might be harmful for HD cells.

Mouse findings

Given how complex a disease like HD is, it’s not surprising that a large number of things change in cells carrying a mutant HD gene. Which of these changes actually matter, and which are a response to being sick?

To solve this problem in the lab, we often use animal models. With model HD mice, it’s possible to introduce experimental drugs or treatments that wouldn’t be ethical to try out in people carrying HD mutations.

So, in this case, Snyder’s team decided to feed some HD mice a diet enriched in cysteine. They reasoned that if the job of CSE is to make cysteine, and CSE levels are down in HD, maybe increasing cysteine levels would be helpful for HD mice.

HD mice fed cysteine in both their food and water did a bit better on some measurements used in the lab to approximate the symptoms of HD. Like human HD patients, HD mice become a bit clumsy as they age. We test this in the lab by having them walk on a spinning rod, like a lumberjack, until they fall off.

In Snyder’s test with cysteine, regular mice were able to walk on the rod for about 125 seconds. As expected, HD mice did worse, only staying on the rod for about 55 seconds or so. Those HD mice who took extra cysteine did better, lasting almost 80 seconds.

The particular version of HD mice used by Snyder’s lab die very early – by about 12-13 weeks all the HD mice had died. Given that the lifespan of a normal mouse can be about 2 years, these are some very sick mice! This is useful, because it lets scientists quickly test ideas in the lab, but it’s not like human HD where people live for a long time before they get sick.

Mice treated with extra cysteine had all died by 15 weeks of age. So they lived a little bit longer than untreated mice, but nowhere near as long as non-HD mice.

All together, giving a rapidly progressing mouse model of HD extra cysteine led to moderate improvements.

Cysteine, cysteamine, what’s the connection?

Raptor Pharmaceuticals, a small biotechnology company, recently announced the results of a human trial with a compound called cysteamine, which sounds an awful lot like cysteine. While cysteine and cysteamine share some parts of their chemical structures, they are different compounds. However, there is interesting data from an earlier mouse study suggesting that feeding mice a precursor of cysteamine leads to increased levels of cysteine in the brain. Still with me?

The idea, so far untested, is that the beneficial effects seen in the cysteamine human trial are related to that compound’s ability to increase cysteine in the brain.

This idea needs a lot more work in mice before we can decide what’s happening in people, but it’s an intriguing hypothesis that you can bet scientists will be following up on.

Complex answer to a simple question

There are always a number of ways to address specific questions in science – some easy and some hard. The current study makes a major proposal, which is that reduced action of the CSE protein leads to a deficiency in the amino acid cysteine, which in turn causes brain cells to die in HD.

So far, this idea has been tested in an “easy” way – by giving HD mice extra cysteine and see if they get better. The authors are currently working on the “hard” way to address this question, which is using genetic tricks to deliver extra copies of the CSE gene to HD mice.

Given the suggestive data in the current study, we guess that this should make mice better. So, we’re excited to add another compound to the list of things that make HD mice a bit better, but remain cautious about the interpretation of these results until we have more information from these on-gong studies.

Bottom line: should HD patients start taking cysteine as a supplement, based on these results? We think the evidence presented thus far is not sufficient, and that additional mouse and human trials are necessary before the risk is worth it.

Latest Research Articles

Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps

Published date: 8 September, 2022

A group of scientists from the EPFL in Lausanne, Switzerland have published a paper in the Journal of the American Chemical Society, describing clumps made up of a fragment of the huntingtin protein. A word that’s commonly used to describe these is “aggregates.” Using very powerful microscopes, the team was able to zoom in and ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Published date: 2 September, 2022

DNA repair and CAG repeat instability The effect of HTT lowering on CAG repeat expansions Welcome to last day of the @hdfcures conference! We’ll only be sharing a few talks from today’s sessions, which focus on DNA repair. The first is from HDBuzz’s very own Jeff Carroll! Jeff will be sharing his work on HTT ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Published date: 1 September, 2022

Pre-clinical work moving toward trials New tools to lower HTT showing promise in animal models Welcome back! The first talk we will be tweeting about today is from Anastasia Khvorova, who will be telling us about her teams work on lowering of Huntingtin using technology called RNAi. One of the problems in studying drug delivery ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 2

Published date: 31 August, 2022

We’re back for day 2 at @hdfcures! This morning’s talks will be focused on clinical trial planning and therapeutic updates from clinical studies. The sheer number of talks related to human trials compared to previous years is so encouraging! Updating metrics for clinical trials A better system for disease categorization The first talk of this ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 1

Published date: 31 August, 2022

Hello and welcome from the HDBuzz team who are currently at the Hereditary Disease Foundation (@hdfcures) 2022 Milton Wexler Biennial Symposium in Boston! It’s the dawn of an exciting new era for HDBuzz. Due to our new partnership with @hdfcures, we are now able to live tweet many of the talks from this meeting which ... Read more

Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials

Published date: 29 August, 2022

Last month, we relayed positive news from uniQure’s trial testing AMT-130, a gene therapy delivered via brain surgery to lower huntingtin (HTT). Data released by uniQure in June suggested AMT-130 was safe and well tolerated in the small group of people that were treated with a low dose of the drug. Now we’re back to ... Read more